144 related articles for article (PubMed ID: 32685125)
1. Pyoderma gangrenosum-like necrotizing panniculitis associated with Imatinib: A case report.
Hernández J; Sanz A; Isla-Tejera B; Ruano J
Dermatol Reports; 2020 Jun; 12(1):8381. PubMed ID: 32685125
[No Abstract] [Full Text] [Related]
2. Adverse skin effects of imatinib, a tyrosine kinase inhibitor.
Pretel-Irazabal M; Tuneu-Valls A; Ormaechea-Pérez N
Actas Dermosifiliogr; 2014 Sep; 105(7):655-62. PubMed ID: 23642471
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
4. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
Mattsson U; Halbritter S; Mörner Serikoff E; Christerson L; Warfvinge G
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May; 111(5):e12-6. PubMed ID: 21330162
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
6. [Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
de Masson A; Bouvresse S; Clérici T; Mahé E; Saïag P
Ann Dermatol Venereol; 2011 Feb; 138(2):135-9. PubMed ID: 21333826
[TBL] [Abstract][Full Text] [Related]
7. Pigmentary changes in a patient treated with imatinib.
Balagula Y; Pulitzer MP; Maki RG; Myskowski PL
J Drugs Dermatol; 2011 Sep; 10(9):1062-6. PubMed ID: 22052279
[TBL] [Abstract][Full Text] [Related]
8. Imatinib Mesylate.
Waller CF
Recent Results Cancer Res; 2018; 212():1-27. PubMed ID: 30069623
[TBL] [Abstract][Full Text] [Related]
9. Lichenoid drug eruption due to imatinib mesylate.
Bhatia A; Kanish B; Chaudhary P
Int J Appl Basic Med Res; 2015; 5(1):68-9. PubMed ID: 25664274
[TBL] [Abstract][Full Text] [Related]
10. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).
Gulati AP; Saif MW
Anticancer Res; 2012 Apr; 32(4):1375-7. PubMed ID: 22493373
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
12. Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML).
El Jurdi N; Bankoff M; Klein A; Saif MW
Cureus; 2016 Jun; 8(6):e660. PubMed ID: 27489753
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate-induced lichenoid drug eruption.
Penn EH; Chung HJ; Keller M
Cutis; 2017 Mar; 99(3):189-192. PubMed ID: 28398413
[TBL] [Abstract][Full Text] [Related]
16. Livedoid skin reaction probably due to imatinib therapy.
Martínez-González MC; del Pozo J; Yebra-Pimentel MT; Pérez M; Almagro M; Fonseca E
Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
Steinert DM; McAuliffe JC; Trent JC
Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
[TBL] [Abstract][Full Text] [Related]
18. New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors.
Inayat F; Saif MW
Anticancer Res; 2016 Nov; 36(11):6201-6204. PubMed ID: 27793952
[TBL] [Abstract][Full Text] [Related]
19. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
[TBL] [Abstract][Full Text] [Related]
20. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
